AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15877873
Drug: Control mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control mineral water (1 litre daily for 8 weeks)
Trial: 8649278
Drug: Intrarectal Quinimax
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal Quinimax 20 mg/kg/12h
Trial: 8649278
Drug: Intrarectal Quinimax
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal Quinimax 8 mg/kg/8h
Trial: 8649278
Drug: Intrarectal Quinimax
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal Quinimax 13 mg/kg/8h
Trial: 8649278
Drug: Intrarectal Quinimax
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal Quinimax 20 mg/kg/8h
Trial: 8649278
Drug: Intramuscular quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular quinine 8 mg/kg/8h
Trial: 8649278
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine 12.5 mg/kg in a slow infusion over 4 hours/12h
Trial: 8649278
Drug: New rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New rectal quinine formulation 12.8 mg/kg/8h quinine gluconate
Trial: 7426887
Drug: Rapid injection
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid injection of meglumine ioxitalamate (380 mg I/ml, 1.5 ml/kg bodyweight) over ten seconds
Trial: 7426887
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection of meglumine ioxitalamate (380 mg I/ml, 1.5 ml/kg bodyweight) over two minutes
Trial: 6151828
Drug: Butofilolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butofilolol (200 mg, administered 24 hours and 2 hours before the test)
Trial: 24488610
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of Cyclosporin-A (2.5 mg/kg)
Trial: 19890345
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with inhaled nitric oxide (20 p.p.m. of iNO)
Trial: 18728103
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (75, 100, 150, or 200 microg)
Trial: 18728103
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (75, 100, 150, or 200 microg)
Trial: 10839333
Drug: Quetiapine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (150 to 600 mg/d)
Trial: 10839333
Drug: Quetiapine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (single dose)
Trial: 1466184
Drug: 3% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% urea cream (HTH lotion 'light')
Trial: 1466184
Drug: 10% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% urea cream (HTH lotion 'Original')
Trial: 24470557
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day) and temsirolimus (50 mg weekly, adjusted based on toxicities)
Trial: 24470557
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day) and temsirolimus (maximum tolerated dosage of 15 mg weekly)
Trial: 19913323
Drug: Viramidine 600
RxNorm normalized name: lidamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viramidine 600 mg twice daily
Trial: 19913323
Drug: Ribavirin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (1000 or 1200 mg/day based on weight)
Trial: 17868354
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic treatment with relief therapy only (Rizatriptan)
Trial: 15507508
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement (Ca-suppl.) of 850 mg/d
Trial: 15507508
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement (Ca-suppl.)
Trial: 1518261
Drug: Chemotherapy (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (9 different intensive chemotherapy regimens)
Trial: 1518261
Drug: Regular maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular maintenance therapy
Trial: 1518261
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy or palliative therapy
Trial: 27306628
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 20 mg orally every week
Trial: 18925348
Drug: Aggression-prevention treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggression-prevention treatment (specific details not provided)
Trial: 16897918
Drug: Computer administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computer administration of the CTS with increased minimum item display duration
Trial: 12837139
Drug: Olanzapine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5 to 10 mg/day)
Trial: 6689091
Drug: 0.1 g
RxNorm normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g of dazoxiben
Trial: 6689091
Drug: 0.25 g
RxNorm normalized name: AMICAR 0.25 GM/mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g or 1.0 g of acetylsalicylic acid (ASA)
Trial: 25924855
Drug: Crown therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crown therapy (both types)
Trial: 23009873
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral ciprofloxacin twice daily for 1 day before and for 2 days after biopsy (group 1)
Trial: 23009873
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg intravenous amikacin 30 minutes before biopsy plus 500 mg oral ciprofloxacin (group 2)
Trial: 17365266
Drug: Conventional cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cream containing 1.15% dithranol, 1.15% salicylic acid and 5.3% coal tar
Trial: 11772135
Drug: Cetirizine 5
RxNorm normalized name: cetirizine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5 mg plus pseudoephedrine SR 120 mg twice daily for 2 to 3 weeks
Trial: 8746927
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate (150 mg/week for two weeks, 300 mg/week for two weeks, and 600 mg/week for two weeks)
Trial: 2183732
Drug: Oral clindamycin
RxNorm normalized name: clindamycin Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clindamycin hydrochloride
Trial: 11138536
Drug: Oral cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cephalexin
Trial: 26429571
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral vitamin D3 supplementation (20,000 IU/week)
Trial: 26429571
Drug: Patients on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on immunomodulatory therapy
Trial: 17707091
Drug: Immunomodulatory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory therapy
Trial: 23835139
Drug: Group psychoeducation
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group psychoeducation over six sessions plus treatment as usual (TAU) (n=19)
Trial: 23835139
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) alone (n=15)
Trial: 17060265
Drug: Sublingual atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual atropine for 48 hours
Trial: 17060265
Drug: Sublingual atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual atropine
Trial: 14965832
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Conformal radiotherapy (CRT) with a total dose of 45-54 Gy given in 8-12 fractions completed in 18-27 days
Trial: 14965832
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Conformal radiotherapy (CRT) with a total dose of 45-54 Gy in 15-18 fractions within 20-25 days
Trial: 11686867
Drug: Soluble recombinant
RxNorm normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble recombinant IL-4 receptor (IL-4 antagonist)
Trial: 1406473
Drug: Catheter removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter removal due to end of therapy
Trial: 24968000
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg moxidectin
Trial: 26645538
Drug: NIRS monitoring
RxNorm normalized name: Nirsevimab
DrugBank: Nirsevimab (DB16258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIRS monitoring with treatment guideline intervention
Trial: 17963428
Drug: Prulifloxacin 600
RxNorm normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 600 mg tablet administered 3 hours before surgery (Group B)
Trial: 17963428
Drug: Prulifloxacin 600
RxNorm normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 600 mg once daily for 3 days (Group C)
Trial: 16225568
Drug: Atosiban (114.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (114.75 mg intravenous infusion) + Labetalol (100 mg orally twice daily)
Trial: 16225568
Drug: Atosiban (114.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (114.75 mg intravenous infusion) + Betamethasone (12 mg intramuscular injection)
Trial: 16225568
Drug: Atosiban (114.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (114.75 mg intravenous infusion)
Trial: 16225568
Drug: Labetalol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (100 mg orally twice daily)
Trial: 16225568
Drug: Betamethasone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (12 mg intramuscular injection)
Trial: 12698990
Drug: FMI (final
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMI (final market image) tablet formulation of oxcarbazepine
Trial: 8657506
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation 10 mg/kg/week intravenously
Trial: 6994982
Drug: Imipramine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (1 mg/kg for 3 weeks)
Trial: 28100342
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of 6 mg nicorandil after guide wire or balloon successfully crossed the target lesion (n=53)
Trial: 28100342
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of 300 μg nitroglycerin after guide wire or balloon successfully crossed the target lesion (n=52)
Trial: 28100342
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (control group, n=53)
Trial: 25880933
Drug: SMT19969 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT19969 (up to 2,000 mg single oral doses)
Trial: 25880933
Drug: SMT19969 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT19969 (200 mg BID for 10 days)
Trial: 25880933
Drug: SMT19969 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT19969 (single and multiple oral doses)
Trial: 25880933
Drug: SMT19969 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT19969 (multiple doses)
Trial: 21214361
Drug: Bimatoprost/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost/timolol fixed combination (BTFC) 0.03%/0.5%
Trial: 19726292
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation of ziprasidone (40 mg)
Trial: 19726292
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation of ziprasidone (40 mg)
Trial: 19726292
Drug: Both test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both test and reference preparations of ziprasidone
Trial: 17846399
Drug: Bupropion hydrochloride,
RxNorm normalized name: BuPROPion Hydrochloride, 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion hydrochloride, 150 mg twice a day
Trial: 15500895
Drug: Regularly scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regularly scheduled albuterol treatment
Trial: 15500895
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of albuterol vs placebo
Trial: 11686808
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (SU)
Trial: 7934734
Drug: Antinicotinic therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antinicotinic therapeutic films containing anabasinum, cytisinum, or their combination in equal ratios applied to the gingiva beneath the upper lip.
Trial: 7934734
Drug: Antinicotinic therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antinicotinic therapeutic films containing cytisinum and anabasinum in combination or cytisinum alone.
Trial: 3602023
Drug: Commercially-available bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially-available bowel evacuant kit (magnesium citrate oral solution, phenolphthalein tablets, bisacodyl suppository)
Trial: 28825891
Drug: Probucol (cholesterol-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (cholesterol-lowering agent) treatment for 6 months
Trial: 23907204
Drug: WBRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBRT + TMZ 75 mg/m² for 2 weeks followed by TMZ 100 mg/m²/day 2 weeks on/2 weeks off for up to 6 months (RCT)
Trial: 21079746
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) and betaine with pegIFNα2b and ribavirin
Trial: 10376694
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment (9 subjects)
Trial: 10376694
Drug: Multiple treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple treatments (58 subjects)
Trial: 8905942
Drug: Eutectic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eutectic mixture of lidocaine and tetracaine (LT ointment) applied 1-2 h before block (group 3)
Trial: 8905942
Drug: Midazolam 5
RxNorm normalized name: midazolam 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 5 mg intramuscularly (groups 2 and 3)
Trial: 367057
Drug: Oxazepam 15
RxNorm normalized name: oxazepam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam 15 mg
Trial: 7144761
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (20 mg/kg i.m. daily during artificial ventilation for up to 14 days)
Trial: 28755266
Drug: Latiglutenase (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latiglutenase (900 mg, n=14)
Trial: 25823136
Drug: Chiropractic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic treatment in addition to dexamethasone and methycobal; chiropractic included local muscle loosening, attacking point, bilateral pulling atlanto-axial joint, continuous treatment for 10 days.
Trial: 25823136
Drug: Dexamethasone intravenous
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone intravenous drip of 10 mg for 3 days, decreased to 5 mg for another 3 days; methycobal intravenous drip of 500 μg for 10 days.
Trial: 18085028
Drug: Prilocaine plus
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prilocaine plus meperidine (Group MP): 5 ml fluid combination containing prilocaine (10 mg/ml) and meperidine (1 mg/kg) injected into nasal packs 15 minutes before removal
Trial: 18085028
Drug: Prilocaine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine (Group P): 5 ml of 1% prilocaine in saline injected into the pack 15 minutes before removal
Trial: 18085028
Drug: Control: 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: 5 ml saline injected into the contra-lateral nostril in both groups
Trial: 23412704
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg single dose
Trial: 23412704
Drug: Placebo 500
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500 mg single dose
Trial: 18461849
Drug: Interdisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary treatment at the Basel clinic
Trial: 17078217
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of bone marrow autologous mononuclear cells (BMAMC) after stenting the coronary artery, performed on AMI day 7-21.
Trial: 17078217
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BMAMC treatment).
Trial: 8883532
Drug: Iodixanol at
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol at 270 mg I/ml
Trial: 8883532
Drug: Iodixanol at
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol at 320 mg I/ml
Trial: 8883532
Drug: Iohexol at
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iohexol at 300 mg I/ml
Trial: 4003142
Drug: 1.32 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.32 mg/kg of 95% USP alcohol
Trial: 30553555
Drug: Low-dose (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (150 mg) pregabalin
Trial: 30553555
Drug: High-dose (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (300 mg) pregabalin
Trial: 22496401
Drug: Early-invitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-invitation group (started receiving food supplements at 9 weeks gestation)
Trial: 22496401
Drug: Usual-invitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-invitation group (started receiving food supplements at 20 weeks gestation)
Trial: 17380562
Drug: Transfusion Risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion Risk Score (TRS) based on clinicopathological factors including preoperative haemoglobin concentration below 12.5 g/dl, largest tumour more than 4 cm, need for exposure of the vena cava, need for an associated procedure, and cirrhosis.
Trial: 12374430
Drug: Cellular replacement
RxNorm normalized name: ISOLYTE E EXTRACELLULAR REPLACEMENT SOLN,INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellular replacement therapy using mesencephalic brain cells from fetal cadavers
Trial: 9520913
Drug: Theophylline (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (plasma concentrations between 15-20 micrograms/ml)
Trial: 2702169
Drug: Fluoride iontophoresis
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride iontophoresis (initial treatment)
Trial: 2702169
Drug: Fluoride iontophoresis
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride iontophoresis (second treatment after 4 weeks)
Trial: 4753234
Drug: Diazepam administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam administration (30 mg or less)
Trial: 4753234
Drug: Diazepam administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam administration (larger doses)
Trial: 23773310
Drug: Morning bright-light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning bright-light therapy (10,000 lux)
Trial: 21612143
Drug: Ketamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.25 mg/Kg
Trial: 21612143
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/Kg
Trial: 21612143
Drug: Ketamine 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.125 mg/Kg
Trial: 23469326
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system (MTS)